Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


18.03.2019

1 BJU Int
1 BMC Cancer
2 Br J Radiol
2 Cancer
1 Cancer Lett
1 Clin Med Insights Oncol
3 Eur Urol
2 Hum Pathol
1 J Clin Lab Anal
3 J Clin Oncol
8 J Nucl Med
2 J Urol
3 N Engl J Med
1 Nat Rev Urol
3 Oncogene
1 Oncol Rep
1 Oncology (Williston Park)
1 PLoS Med
2 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. HUGHES SR
    2018: A Spacer Odyssey.
    BJU Int. 2018;122:353-354.
    PubMed     Text format    


    BMC Cancer

  2. MAMIDI TKK, Wu J, Hicks C
    Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
    BMC Cancer. 2019;19:229.
    PubMed     Text format     Abstract available


    Br J Radiol

  3. FRANZESE C, D'agostino G, Di Brina L, Navarria P, et al
    Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity.
    Br J Radiol. 2019 Mar 13:20190021. doi: 10.1259/bjr.20190021.
    PubMed     Text format     Abstract available

  4. JI Y, Litao R, Ren W, Dun G, et al
    Stiffness of prostate gland measured by transrectal Real-Time shear wave elastography for detection of prostate cancer: A feasibility study.
    Br J Radiol. 2019 Mar 15:20180970. doi: 10.1259/bjr.20180970.
    PubMed     Text format     Abstract available


    Cancer

  5. JANG TL, Kim IY, Scardino PT, Eastham JA, et al
    Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
    Cancer. 2019 Mar 12. doi: 10.1002/cncr.32054.
    PubMed     Text format    

  6. DE CICCO L
    Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
    Cancer. 2019 Mar 12. doi: 10.1002/cncr.32055.
    PubMed     Text format    


    Cancer Lett

  7. SHAO J, Zhu W, Ding Y, Zhu H, et al
    Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway.
    Cancer Lett. 2019 Mar 6. pii: S0304-3835(19)30128.
    PubMed     Text format     Abstract available


    Clin Med Insights Oncol

  8. EL-AMM J, Aragon-Ching JB
    The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer.
    Clin Med Insights Oncol. 2019;13:1179554919833927.
    PubMed     Text format     Abstract available


    Eur Urol

  9. MOON DH, Basak RS, Usinger DS, Dickerson GA, et al
    Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
    Eur Urol. 2019 Mar 8. pii: S0302-2838(19)30169.
    PubMed     Text format     Abstract available

  10. KASS-ILIYYA A, Jovic G, Murphy C, Fisher C, et al
    Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
    Eur Urol. 2018;73:968-976.
    PubMed     Text format     Abstract available

  11. SHARMA V, Nehra A, Colicchia M, Westerman ME, et al
    Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Eur Urol. 2018;73:879-887.
    PubMed     Text format     Abstract available


    Hum Pathol

  12. MCCROSKEY Z, Koen TM, Lim DJ, Divatia MK, et al
    Prostatic adenocarcinoma in the setting of persistent mullerian duct syndrome: a case report.
    Hum Pathol. 2018;75:125-131.
    PubMed     Text format     Abstract available

  13. KAUR HB, Lu J, Guedes LB, Maldonado L, et al
    TP53 missense mutation is associated with increased tumor-infiltrating T-cells in primary prostate Cancer.
    Hum Pathol. 2019 Mar 6. pii: S0046-8177(19)30023.
    PubMed     Text format     Abstract available


    J Clin Lab Anal

  14. GRIVAS N, de Bruin D, Barwari K, van Muilekom E, et al
    Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up.
    J Clin Lab Anal. 2019;33:e22693.
    PubMed     Text format     Abstract available


    J Clin Oncol

  15. ARMSTRONG AJ, Halabi S, Luo J, Nanus DM, et al
    Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
    J Clin Oncol. 2019 Mar 13:JCO1801731. doi: 10.1200/JCO.18.01731.
    PubMed     Text format     Abstract available

  16. ROSENTHAL SA, Hu C, Sartor O, Gomella LG, et al
    Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
    J Clin Oncol. 2019 Mar 12:JCO1802158. doi: 10.1200/JCO.18.02158.
    PubMed     Text format     Abstract available

  17. JAYADEVAPPA R, Chhatre S, Gallo JJ, Wittink M, et al
    Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2019 Mar 12:JCO1801091. doi: 10.1200/JCO.18.01091.
    PubMed     Text format     Abstract available


    J Nucl Med

  18. LUTJE S, Gerrits D, Molkenboer-Kuenen JD, Herrmann K, et al
    Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    J Nucl Med. 2018;59:494-501.
    PubMed     Text format     Abstract available

  19. WEBER W
    2017 SNMMI Highlights Lecture: Oncology.
    J Nucl Med. 2018;59:7N-13N.
    PubMed     Text format    

  20. WEBER W
    2017 SNMMI Highlights Lecture: Oncology, Part 2.
    J Nucl Med. 2018;59:9N-15N.
    PubMed     Text format    

  21. GAFITA A, Bieth M, Kroenke M, Tetteh G, et al
    qPSMA: a semi-automatic software for whole-body tumor burden assessment in prostate cancer using (68)Ga-PSMA11 PET/CT.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224055. doi: 10.2967/jnumed.118.224055.
    PubMed     Text format     Abstract available

  22. EKMEKCIOGLU O, Busstra M, Klass ND, Verzijlbergen F, et al
    Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence - a narrative review of literature.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.222885. doi: 10.2967/jnumed.118.222885.
    PubMed     Text format     Abstract available

  23. ZHANG J, Kulkarni HR, Singh A, Schuchardt C, et al
    (177)Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.223149. doi: 10.2967/jnumed.118.223149.
    PubMed     Text format     Abstract available

  24. SCHWENCK J, Olthof SC, Pfannenberg C, Reischl G, et al
    Intention to treat analysis of (68)Ga-PSMA and (11)C-choline PET/CT versus CT for prostate cancer recurrences after surgery.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224543. doi: 10.2967/jnumed.118.224543.
    PubMed     Text format     Abstract available

  25. KRAMER GM, Yaqub M, Vargas HA, Schuit R, et al
    Assessment of simplified methods for quantification of (18)F-FDHT uptake in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.220111. doi: 10.2967/jnumed.118.220111.
    PubMed     Text format     Abstract available


    J Urol

  26. TANEJA SS
    Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    J Urol. 2019 Mar 13:101097JU0000000000000231. doi: 10.1097/JU.0000000000000231.
    PubMed     Text format    

  27. HELFAND BT
    Editorial Comment.
    J Urol. 2019;201:494.
    PubMed     Text format    


    N Engl J Med

  28. CHARKES ND
    Radical Surgery or Watchful Waiting in Prostate Cancer.
    N Engl J Med. 2019;380:1084.
    PubMed     Text format    

  29. YANG Z, McCaw ZR, Yin G
    Radical Surgery or Watchful Waiting in Prostate Cancer.
    N Engl J Med. 2019;380:1083-1084.
    PubMed     Text format    

  30. BILL-AXELSON A, Holmberg L, Garmo H
    Radical Surgery or Watchful Waiting in Prostate Cancer. Reply.
    N Engl J Med. 2019;380:1084.
    PubMed     Text format    


    Nat Rev Urol

  31. EMBERTON M
    To see or not to see - what renders prostate cancer visible?
    Nat Rev Urol. 2019 Mar 13. pii: 10.1038/s41585-019-0167.
    PubMed     Text format    


    Oncogene

  32. LV S, Ji L, Chen B, Liu S, et al
    Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
    Oncogene. 2018;37:1354-1368.
    PubMed     Text format     Abstract available

  33. WANG HJ, Pochampalli M, Wang LY, Zou JX, et al
    KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
    Oncogene. 2019;38:17-32.
    PubMed     Text format     Abstract available

  34. SINHA KM, Bagheri-Yarmand R, Lahiri S, Lu Y, et al
    Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.
    Oncogene. 2019 Mar 11. pii: 10.1038/s41388-019-0774.
    PubMed     Text format     Abstract available


    Oncol Rep

  35. SUN W, Li L, Du Z, Quan Z, et al
    Combination of phospholipase Cepsilon knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Oncol Rep. 2019 Mar 7. doi: 10.3892/or.2019.7054.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  36. CONSIDINE B, Petrylak DP
    Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer.
    Oncology (Williston Park). 2019;33.
    PubMed     Text format     Abstract available


    PLoS Med

  37. THURTLE DR, Greenberg DC, Lee LS, Huang HH, et al
    Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.
    PLoS Med. 2019;16:e1002758.
    PubMed     Text format     Abstract available


    Prostate

  38. SCHWEIZER MT, Gulati R, Beightol M, Konnick EQ, et al
    Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
    Prostate. 2019 Mar 13. doi: 10.1002/pros.23778.
    PubMed     Text format     Abstract available

  39. CAMPOLINA-SILVA GH, Maria BT, Mahecha GAB, Oliveira CA, et al
    Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging-related prostate lesions.
    Prostate. 2018;78:532-546.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: